Business

Q1 results lower year on year, as expected; Comprehensive action plan underway to address market challenges

Regulated information Growth in adult care offset by continued softness in baby care and expected decline in contract manufacturing, resulting in 4% LFL revenue decrease year on year; Capacity ramp‑up continued in adult care to support future growth;Adjusted EBITDA margin of 9.1%, down 2.2pp year on year, and stable quarter on quarter; Efficiency initiatives accelerated to improve profitability;Net debt reduced by a further 5% over the quarter to €550 million, strengthening the balance sheet; Ac

articleGsk PlcApril 29, 20269/company/glaxosmithkline-plc/news/q1-results-lower-year-on-year-as-expected-comprehensive-action-plan-underway-to-address-market-challenges
Q1 results lower year on year, as expected; Comprehensive action plan underway to address market challenges

About this update from Gsk Plc

[{"type":"image","alt":"Ontex","displaySize":"","headline":null,"caption":"Ontex","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/f42cbfb42a07158e5b79575b95493735"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cywpt8LD9p95JSYQ7Bs8Nw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MQ--/https://media.zenfs.com/en/globenewswire.com/f42cbfb42a07158e5b79575b95493735","width":300,"height":115}},"lazy":false},{"type":"text","content":"Regulated information","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Growth in adult care offset by continued softness in baby care and expected decline in contract manufacturing, resulting in 4% LFL revenue decrease year on year; Capacity ramp‑up continued in adult care to support future growth;","length":228,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA margin of 9.1%, down 2.2pp year on year, and stable quarter on quarter; Efficiency initiatives accelerated to improve profitability;","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Net debt reduced by a further 5% over the quarter to €550 million, strengthening the balance sheet; Actions taken to further optimize working capital management;","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Based on current market visibility and subject to gradual easing of the energy crisis, full‑year outlook maintained; Ontex actively mitigating higher costs through pricing actions;","length":180,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategic review on track: Initial actions launched, and more to be shared at Q2 results publication.","length":101,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":818,"olType":false},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"CEO quote","length":9,"tagName":"p"},{"type":"text","content":"Laurent Nielly, Ontex’s CEO, said: “Our performance is clearly not yet at the level we aspire it to be, but in a quarter with new geopolitical instability and market demand a bit softer than expected, I am encouraged by the work of our teams to make Ontex resilient and deliver the anticipated profit level. We have a strong supply chain to navigate potential supply pressure and we have proven cost mitigation and targeted pricing capabilities t...

More updates from Gsk Plc

Ontexmarket demandbaby caremarket visibilityEBITDA marginworking capital management